Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$5.53
+1.0%
$4.56
$1.03
$5.97
$1.29B1.584.02 million shs2.10 million shs
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.25
-1.3%
$0.29
$0.10
$0.49
$318.09M1.372.62 million shs1.07 million shs
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$46.13
+0.0%
$39.16
$16.53
$50.40
$1.31B0.5319,766 shs144,254 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$16.45
-1.4%
$14.82
$9.03
$17.70
$1.24B1.51537,236 shs285,782 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
+4.59%+0.37%+19.69%+107.98%+371.55%
CytoDyn Inc. stock logo
CYDY
CytoDyn
-1.58%-0.85%-19.12%-16.81%+65.20%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-5.40%+2.72%+9.84%+47.03%+78.86%
Zymeworks Inc. stock logo
ZYME
Zymeworks
-1.53%-3.19%+10.83%+28.80%+32.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$5.53
+1.0%
$4.56
$1.03
$5.97
$1.29B1.584.02 million shs2.10 million shs
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.25
-1.3%
$0.29
$0.10
$0.49
$318.09M1.372.62 million shs1.07 million shs
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
$46.13
+0.0%
$39.16
$16.53
$50.40
$1.31B0.5319,766 shs144,254 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$16.45
-1.4%
$14.82
$9.03
$17.70
$1.24B1.51537,236 shs285,782 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
+4.59%+0.37%+19.69%+107.98%+371.55%
CytoDyn Inc. stock logo
CYDY
CytoDyn
-1.58%-0.85%-19.12%-16.81%+65.20%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-5.40%+2.72%+9.84%+47.03%+78.86%
Zymeworks Inc. stock logo
ZYME
Zymeworks
-1.53%-3.19%+10.83%+28.80%+32.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
2.86
Moderate Buy$11.25103.62% Upside
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00
N/AN/AN/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
2.67
Moderate Buy$49.607.52% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.4330.26% Upside

Current Analyst Ratings Breakdown

Latest CYDY, ZYME, LENZ, and ATAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/27/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/23/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$15.00
8/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/11/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$19.00 ➝ $22.00
7/31/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00 ➝ $49.00
7/31/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$39.00 ➝ $40.00
7/30/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00 ➝ $15.00
7/29/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$14.00
7/28/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$12.00 ➝ $11.00
7/28/2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$38.00 ➝ $48.00
(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$310K4,166.56N/AN/A$0.69 per share8.01
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/A($0.08) per shareN/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/A$7.42 per shareN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
$122.87M10.06N/AN/A$6.63 per share2.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$149.27M-$0.69N/AN/AN/AN/A-85.43%-64.38%11/12/2025 (Estimated)
CytoDyn Inc. stock logo
CYDY
CytoDyn
$3.74M$0.0125.28N/AN/AN/A-4.40%10/15/2025 (Estimated)
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)

Latest CYDY, ZYME, LENZ, and ATAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.28N/AN/AN/AN/AN/A
8/14/2025Q2 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.12-$0.14-$0.02-$0.14N/A$0.72 million
8/7/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.52$0.03+$0.55N/A$17.18 million$48.73 million
7/30/2025Q2 2025
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 million
7/25/2025Q4 2025
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A-$0.01N/A-$0.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
N/AN/AN/AN/AN/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/A
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
0.02
4.02
4.02
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A
0.25
0.25
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
N/A
20.54
20.54
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
28.41%
CytoDyn Inc. stock logo
CYDY
CytoDyn
5.06%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
54.32%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
26.80%
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.54%
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
6.90%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
80233.78 million171.13 millionOptionable
CytoDyn Inc. stock logo
CYDY
CytoDyn
201.26 billion1.25 billionNot Optionable
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
11028.52 million26.55 millionN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
46075.17 million67.56 millionOptionable

Recent News About These Companies

Brokerages Set Zymeworks Inc. (NYSE:ZYME) Target Price at $21.43
Bloom Burton Remains a Buy on Zymeworks (ZYME)
Brokers Set Expectations for Zymeworks FY2025 Earnings
Zymeworks Reports Q2 Results and FDA Clearance

New MarketBeat Followers Over Time

Media Sentiment Over Time

atai Life Sciences stock logo

atai Life Sciences NASDAQ:ATAI

$5.52 +0.06 (+1.01%)
As of 12:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

CytoDyn stock logo

CytoDyn OTCMKTS:CYDY

$0.25 0.00 (-1.33%)
As of 12:16 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

LENZ Therapeutics stock logo

LENZ Therapeutics NASDAQ:LENZ

$46.13 +0.02 (+0.05%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$16.45 -0.24 (-1.44%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.